ConductScience.org, home

Paper12840682

A pilot trial of Saccharomyces boulardii in ulcerative colitis.

Guslandi M and 2 others. Eur J Gastroenterol Hepatol, 2003. Cited by 239 papers, by iCite.

Cite this record

ConductScience Library. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Papers, record 12840682. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/12840682

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A pilot trial of Saccharomyces boulardii in ulcerative colitis.
PubMed
Journal
Eur J Gastroenterol Hepatol
PubMed
Year
2003
PubMed
Publication types
Clinical Trial, Journal Article
PubMed
Citations, by iCite
239
iCite
Relative citation ratio, by iCite
5.88
iCite
Revised in PubMed
2019-09-06
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Guslandi MMario
2Giollo PPatrizia
3Testoni PAPier Alberto

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Colitis, UlcerativeMajor topic
ProbioticsMajor topic
SaccharomycesMajor topic
Adult
Anti-Inflammatory Agents, Non-Steroidal
Combined Modality Therapy
Female
Humans
Male
Mesalamine
Middle Aged
Pilot Projects
Remission Induction

Source PubMed

Download CSV of topics

Cited by94

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 239 citations.

PMIDTitleJournalYearIn PapersSource
42941735Surface Display of an Anti-CD3 scFv by Saccharomyces boulardii and Its Effect on DSS-Induced Colitis in Mice.Int J Mol Sci2026https://conductscience.org/library/papers/42941735PubMed
42404519Protein-losing enteropathy after the Fontan procedure - A cardiologist's and gastroenterologist's perspective.Ann Pediatr Cardiol2026https://conductscience.org/library/papers/42404519PubMed
42377935Yeasts in the gastrointestinal tract.FEMS Yeast Res2026https://conductscience.org/library/papers/42377935PubMed
41749264Cross-kingdom microbial interactions in the gut during inflammatory bowel disease.J Transl Med2026https://conductscience.org/library/papers/41749264PubMed
41176278Dietary and Lifestyle Risk Factors in Primary Sclerosing Cholangitis: In Search of Mechanistic Explanations and Health Improvement.J Nutr2025https://conductscience.org/library/papers/41176278PubMed
40885775Engineered spermidine-secreting Saccharomyces boulardii ameliorates colitis and colon cancer in mice.Sci Rep2025https://conductscience.org/library/papers/40885775PubMed
40872558Saccharomyces boulardii CNCM I-745 Supernatant Improves Markers of Gut Barrier Function and Inflammatory Response in Small Intestinal Organoids.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/40872558PubMed
40806413The Human Mycobiome: Composition, Immune Interactions, and Impact on Disease.Int J Mol Sci2025https://conductscience.org/library/papers/40806413PubMed
40624229Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma.Nat Rev Gastroenterol Hepatol2025https://conductscience.org/library/papers/40624229PubMed
40530243Multi-step pathway engineering in probiotic Saccharomyces boulardii for abscisic acid production in the gut.Metab Eng Commun2025https://conductscience.org/library/papers/40530243PubMed
40383233Enabling technologies for in situ biomanufacturing using probiotic yeast.Adv Drug Deliv Rev2025https://conductscience.org/library/papers/40383233PubMed
40065908Saccharomyces boulardii Alleviates Colitis by Regulating FXR-NLRP3 Mediated Macrophage Pyroptosis.J Inflamm Res2025https://conductscience.org/library/papers/40065908PubMed
39770617Heterologous Expression of the Antiviral Lectin Griffithsin in Probiotic Saccharomyces boulardii and In Vitro Characterization of Its Properties.Microorganisms2024https://conductscience.org/library/papers/39770617PubMed
39193472The gut-lung axis: the impact of the gut mycobiome on pulmonary diseases and infections.Oxf Open Immunol2024https://conductscience.org/library/papers/39193472PubMed
38752748Enhancing probiotic impact: engineering Saccharomyces boulardii for optimal acetic acid production and gastric passage tolerance.Appl Environ Microbiol2024https://conductscience.org/library/papers/38752748PubMed
38585636Probiotics for inflammatory bowel disease: Is there sufficient evidence?Open Life Sci2024https://conductscience.org/library/papers/38585636PubMed
38409485A comprehensive guide to assess gut mycobiome and its role in pathogenesis and treatment of inflammatory bowel disease.Indian J Gastroenterol2024https://conductscience.org/library/papers/38409485PubMed
37935653Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease.Intest Res2024https://conductscience.org/library/papers/37935653PubMed
36651453Could paraprobiotics be a safer alternative to probiotics for managing cancer chemotherapy-induced gastrointestinal toxicities?Braz J Med Biol Res2023https://conductscience.org/library/papers/36651453PubMed
36565724Fungal infections and the fungal microbiome in hepatobiliary disorders.J Hepatol2023https://conductscience.org/library/papers/36565724PubMed

See all 94 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/12840682

GET https://conductscience.org/api/papers/v1/12840682/cited_by?page=2